China Pharma Pure Powder manufacturer

USP Marbofloxacin Powder , Antibacterial Marbofloxacin Veterinary Use 115550-35-1

Product Details:
Place of Origin: Xi'An,China
Brand Name: wango
Certification: USP, BP
Model Number: WG-0015
Payment & Shipping Terms:
Minimum Order Quantity: 1kilogram every time
Price: FOB price 620-650usd/kg ,can be Negotiable .
Packaging Details: 10-1000 gram Aluminum Foil Bag Packaging by TNT or DHL , 25kilogram per drum .
Delivery Time: 3-5 working days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 1000kilogram every month

Detail Information

Usage: Veterinary Colour: Yellow Fine Powder
Function: Antibacterial Powder Cas: 115550-35-1
High Light:

USP Marbofloxacin Powder

,

USP 115550-35-1

,

Antibacterial Marbofloxacin Veterinary Use

Product Description

Marbofloxacin Treating Dogs And Cats And For Urinary Tract Infections veterinary Medicine Cas 115550-35-1 2000kg fresh stock of the 2021 year

 

USP Marbofloxacin Powder , Antibacterial Marbofloxacin Veterinary Use 115550-35-1 0

 

Name of Product:

Marbofloxacin

Shelf Life:

5 years

Specification:

EP8

Test Items

Specification

Results of Analysis

Appearance

Light yellow crystalline powder

Conforms

Solubility

Slightly soluble in water, sparingly soluble or slightly soluble in methylene chloride, very slightly soluble in ethanol (96 percent)

Conforms

Identification

Conforms to the marbofloxacin CRS

Conforms

Absorbance

≤0.20

0.08

Loss on drying

≤0.5%

0.12%

Sulphated ash

≤0.1%

0.05%

Heavy metals

≤20ppm

<20ppm

Related substance (HPLC)

Impurity A≤0.1%

Not detected

Impurity B≤0.1%

Not detected

Impurity C≤0.2%

0.06%

Impurity D≤0.2%

Not detected

Impurity E≤0.2%

Not detected

Any other single impurity≤0.2%

Not detected

Total impurities≤0.5%

0.06%

Residual solvents

ethanol≤5000ppm

309ppm

toluene≤890ppm

457ppm

methylene chloride≤600ppm

Not detected

Assay

99.0% to 101.0% (dried substance)

100%

 

 

DESCRIPTION

Marbofloxacin is a synthetic broad-spectrum antibacterial agent from the fluoroquinolone class of chemotherapeutic agents. Marbofloxacin is the non-proprietary designation for 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2] benzoxadiazine-6-carboxylic acid. The empirical formula is C17H19FN4O4 and the molecular weight is 362.36. The compound is soluble in water; however, solubility decreases in alkaline conditions. The N-octanol/water partition coefficient (Kow) is 0.835 measured at pH 7 and 25°C.

Figure 1: Chemical structure of marbofloxacin

 

CLINICAL PHARMACOLOGY

Marbofloxacin is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration to fasted animals. Divalent cations are generally known to diminish the absorption of fluoroquinolones. The effects of concomitant feeding on the absorption of marbofloxacin have not been determined. (See Drug Interactions.) In the dog, approximately 40% of an oral dose of marbofloxacin is excreted unchanged in the urine1. Excretion in the feces, also as unchanged drug, is the other major route of elimination in dogs. Ten to 15% of marbofloxacin is metabolized by the liver in dogs.

In vitro plasma protein binding of marbofloxacin in dogs was 9.1% and in cats was 7.3%. In the cat, approximately 70% of an oral dose is excreted in the urine as marbofloxacin and metabolites with approximately 85% of the excreted material as unchanged drug. Pharmacokinetic parameters related to intravenous dosing were estimated in a study of 6 healthy adult beagle dogs, and are summarized in Table 1. The absolute bioavailability following dosing of oral tablets to the same animals was 94%.

Marbofloxacin plasma concentrations were determined over time in healthy adult beagle dogs (6 dogs per dosage group) following single oral doses of 1.25 mg/lb or 2.5 mg/lb. Absorption of orally administered marbofloxacin increases proportionally over the dose range of 1.25 to 2.5 mg/lb. Marbofloxacin plasma concentrations were determined over time in 7 healthy adult male cats following a single oral dose of 2.5 mg/lb. Plasma pharmacokinetic parameters following oral dosing of dogs and cats are summarized in Figures 2 and 3 and in Table 2. Based on the terminal elimination half-life and the dosing interval, steady-state levels are reached after the third dose and are expected to be approximately 25% greater in dogs and 35% greater in cats than those achieved after a single dose. Marbofloxacin is widely distributed in canine tissues. Tissue concentrations of marbofloxacin were determined in healthy male beagle dogs (4 dogs per time period) at 2, 18 and 24 hours after a single oral dose (1.25 or 2.5 mg/lb) and are summarized in Tables 3a and 3b.

Table 1: Mean pharmacokinetic parameters following intravenous administration of marbofloxacin to 6 adult beagle dogs at a dosage of 2.5 mg/lb.

Parameter

Estimate ± SD* n=6

Total body clearance, (mL/h•kg)

94 ± 8

Volume of distribution at steady state, Vss, (L/kg)

1.19 ± 0.08

AUC0-inf (μg•h/mL)

59 ± 5

Terminal plasma elimination half-life, t1/2(h)

9.5 ± 0.7

* SD = standard deviation

Table 2: Mean pharmacokinetic parameters following oral administration of marbofloxacin tablets to adult beagle dogs at a nominal dosage of 1.25 mg/lb or
2.5 mg/lb and to cats at 2.5 mg/lb.

 

 

 

 

Parameters

Dog Estimate ± SD* (1.25 mg/lb) n=6

Dog Estimate ± SD* (2.5 mg/lb) n=6

Cat Estimate ± SD* (2.5 mg/lb) n=7

Time of maximum concentration, Tmax(h)

1.5 ± 0.3

1.8 ± 0.3

1.2 ± 0.6

Maximum concentration, Cmax, (μg/mL)

2.0 ± 0.2

4.2 ± 0.5

4.8 ± 0.7

AUC0-inf (μg•h/mL)

31.2 ± 1.6

64 ± 8

70 ± 6

Terminal plasma elimination half-life, t1/2(h)

10.7 ± 1.6

10.9 ± 0.6

12.7 ± 1.1

mean actual dosages administered to dogs were 1.22 mg/lb and 2.56 mg/lb, respectively, and the mean
actual dosage administered to cats was 2.82 mg/lb.
* SD = standard deviation

Figure 2: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult beagle dogs at dosages of 1.25 mg/lb or 2.5 mg/lb.

* See Table 4 in Microbiology section for MIC data.

Figure 2.

Figure 3: Mean plasma concentrations (µg/mL) following single oral administration of marbofloxacin to adult cats at a dosage of 2.5 mg/lb.

* See Table 5 in Microbiology section for MIC data.

Figure 3.

Table 3a: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 1.25 mg/lb*.

Tissue

Marbofloxacin 2 hours (n=4)

Concentrations 18 hours (n=4)

(μg/g ± SD) 24 hours (n=4)

bladder

4.8 ± 1.1

2.6 ± 1.5

1.11 ± 0.19

bone marrow

3.1 ± 0.5

1.5 ± 1.5

0.7 ± 0.2

feces

15 ± 9

48 ± 40

26 ± 11

jejunum

3.6 ± 0.5

1.3 ± 1.0

0.7 ± 0.3

kidney

7.1 ±1.7

1.4 ± 0.5

0.9 ± 0.3

lung

3.0 ± 0.5

0.8 ± 0.2

0.57 ± 0.19

lymph node

5.5 ± 1.1

1.3 ± 0.3

1.0 ± 0.3

muscle

4.1 ± 0.3

1.0 ± 0.3

0.7 ± 0.2

prostate

5.6 ± 1.4

1.8 ± 0.6

1.1 ± 0.4

skin

1.9 ± 0.6

0.41 ± 0.13

0.32 ± 0.08

* SD = standard deviation

Table 3b: Tissue distribution following a single oral administration of marbofloxacin tablets to adult beagle dogs at a dosage of 2.5 mg/lb.

Tissue

Marbofloxacin 2 hours (n=4)

Concentrations 18 hours (n=4)

(μg/g ± SD*) 24 hours (n=4)

bladder

12 ± 4

6 ± 7

1.8 ± 0.4

bone marrow

4.6 ± 1.5

1.28 ± 0.13

0.9 ± 0.3

feces

18 ± 3

52 ± 17

47 ± 28

jejunum

7.8 ± 1.1

2.0 ± 0.3

1.1 ± 0.3

kidney

12.7 ±1.7

2.7 ± 0.3

1.6 ± 0.2

lung

5.48 ± 0.17

1.45 ± 0.19

1.0 ± 0.2

lymph node

8.3 ± 0.7

2.3 ± 0.5

2.03 ± 0.06

muscle

7.5 ± 0.5

1.8 ± 0.3

1.20 ± 0.12

prostate

11 ± 3

2.7 ± 1.0

2.0 ± 0.5

skin

3.20 ± 0.33

0.705 ± 0.013

0.46 ± 0.09

* SD = standard deviation

 

Microbiology

The primary action of fluoroquinolones is to inhibit the bacterial enzyme, DNA gyrase. In susceptible organisms, fluoroquinolones are rapidly bactericidal at relatively low concentrations. Marbofloxacin is bactericidal against a broad range of gram-negative and gram-positive organisms. The minimum inhibitory concentrations (MICs) of pathogens isolated in clinical field studies performed in the United States were determined using National Committee for Clinical Laboratory Standards (NCCLS) standards, and are shown in Tables 4 and 5.

Table 4. MIC Values* (μg/mL) of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs enrolled in clinical studies conducted during 1994–1996.

Organism

No. of Isolates

MIC50

MIC90

MIC Range

Staphylococcus intermedius

135

0.25

0.25

0.125-2

Escherichia coli

61

0.03

0.06

0.015-2

Proteus mirabilis

35

0.06

0.125

0.03-0.25

Beta-hemolytic Streptococcus,

(not Group A or Group B)

25

1

2

0.5-16

Streptococcus,

Group D enterococcus

16

1

4

0.008-4

Pasteurella multocida

13

0.015

0.06

≤0.008-0.5

Staphylococcus aureus

12

0.25

0.25

0.25-0.5

Enterococcus faecalis

11

2

2

1-4

Klebsiella pneumonia

11

0.06

0.06

0.01-0.06

Pseudomonas spp.

9

**

**

0.06-1

Pseudomonas aeruginosa

7

**

**

0.25-1

* The correlation between in vitro susceptibility data (MIC) and clinical response has not been
determined.
** MIC50 and MIC90 not calculated due to insufficient number of isolates.

Table 5: MIC Values* (μg/mL) of marbofloxacin against pathogens isolated from
skin and soft tissue infections in cats enrolled in clinical studies conducted in 1995
and 1998.

Organism

No. of Isolates

MIC50

MIC90

MIC Range

Pasteurella multocida

135

0.03

0.06

≤0.008-0.25

Beta-hemolytic Streptococcus

22

1

1

0.06-1

Staphylococcus aureus

21

0.25

0.5

0.125-1

Corynebacterium spp.

14

0.5

1

0.25-2

Staphylococcus intermedius

11

0.25

0.5

0.03-0.5

Enterococcus faecalis

10

2.0

2.0

1.0-2.0

Escherichia coli

10

0.03

0.03

0.015-0.03

Bacillus spp.

10

0.25

0.25

0.125-0.25

STORAGE CONDITIONS

Store below 30°C (86°F).

 

HOW SUPPLIED

Zeniquin tablets are available in the following strengths of marbofloxacin and bottle sizes:

25 mg scored tablets supplied in bottles that contain 100 or 250 tablets
50 mg scored tablets supplied in bottles that contain 100 or 250 tablets
100 mg scored tablets supplied in a 50 tablet bottle
200 mg scored tablets supplied in a 50 tablet bottle

 

USP Marbofloxacin Powder , Antibacterial Marbofloxacin Veterinary Use 115550-35-1 3

 

 

 

 

Get in touch with us

Enter Your Message

You Might Be Into These